• About us
• Contact

Advertisement

Product › Details

IFX-1 (InflaRx)

	Next higher product group	therapeutic antibody
	Status	2014-01-01 development p2 start
	Organisation	InflaRx GmbH
	Group	InflaRx (Group)

Record changed: 2023-07-10

Advertisement

More documents for IFX-1 (InflaRx)

• [1] InflaRx N.V.. (9/17/20). "Press Release: InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer". Jena....
• [2] InflaRx N.V.. (3/31/20). "Press Release: InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology". Jena....
• [3] InflaRx N.V.. (6/5/19). "Press Release: InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa". Jena....
• [4] InflaRx N.V.. (2/6/19). "Press Release: InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [5] InflaRx N.V.. (1/3/19). "Press Release: InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management". Jena & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.